t(11;14)

MCL Literature Feed

846 papers on mantle cell lymphoma from PubMed. Updated daily.

ADCBCL2iBTKiCAR-TCDK4/6iCNSMRDPI3KiTP53-mutatedbiomarkersbispecificblastoidcase reportchemotherapyconsolidationelderlyepidemiologyfrontlinegenomicsguidelines
Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.
Simona Andrea Ruckstuhl, Katja Seipel, Inna Shaforostova et al.·Cancers·Jun 29, 2026
Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.
Azhagu Madhavan Sivalingam·Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jun 24, 2026
Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.
Olga Kersy, Nir Cohen, Mali Salmon-Divon et al.·Blood advances·Jun 23, 2026
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Angély Loubert, Kristin Creel, Naleen Raj Bhandari et al.·Journal of patient-reported outcomes·Jun 22, 2026
Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation.
Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong et al.·Annals of hematology·Jun 19, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Stephen D Smith, Suchitra Sundaram, Sharmila Giri et al.·American journal of hematology·Jun 17, 2026
FDA Announces Efforts to Implement Real-Time Clinical Trial Reporting.
·Cancer discovery·Jun 17, 2026
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.
Zijun Y Xu-Monette, Chang Wang, Dehong Wu et al.·Blood advances·Jun 16, 2026
Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade.
Dan Lin, Changxia Shao, Jiemin Ma et al.·Cancer treatment and research communications·Jun 16, 2026
The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.
Tadeusz Robak, Paweł Robak·Expert opinion on drug discovery·Jun 15, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Where next for BTKi-BCL2i combinations in mantle cell lymphoma?
Toby A Eyre·British journal of haematology·Jun 14, 2026
Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma.
Mingxin Zhang, Yuan Chen·British journal of haematology·Jun 14, 2026
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.
Fabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi et al.·The Lancet. Haematology·Jun 12, 2026
LncRNA IRAIN inhibits mantle cell lymphoma progression by inducing cell cycle arrest and apoptosis: an in vitro study.
Ping Lin, Yiping Zhang, Liling Lu et al.·Scientific reports·Jun 9, 2026
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.
Eva Pokorna, Dmitry Manakov, Kristyna Nozickova et al.·Scientific reports·Jun 8, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.
Di Wang, Haochen Wu, MengHan Li et al.·Annals of hematology·Jun 5, 2026
CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.
V Rakesh Sethapati, Vu Ngo, Alexey Danilov et al.·American journal of clinical pathology·Jun 4, 2026
Ibrutinib improves overall survival in patients with mantle cell lymphoma.
Peter Sidaway·Nature reviews. Clinical oncology·Jun 3, 2026
Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.
Shucen Wan, Seema Naik·International journal of molecular sciences·Jun 2, 2026
Orbital infiltration in relapsed mantle cell lymphoma.
Francisco Calleja-Casado, Jonathan Molina García, Diego Serrano Fernando·Orbit (Amsterdam, Netherlands)·Jun 2, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.
Enver Aydilek, Paolo Mazzeo, Justin Hasenkamp et al.·EJHaem·Jun 1, 2026
CAR T-cell therapy-associated central hypothyroidism: a case of a novel onco-endocrine toxicity.
Maria Martinez-Cruz, Lauren Mozingo, Courtney Dominguez et al.·JCEM case reports·Jun 1, 2026
Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma.
Wen-Wen Zhang, Long-Feng Ke, Chen-Yu Wu et al.·Pathology·Jun 1, 2026
Modern Management of Mantle Cell Lymphoma.
Tobias Tix, Anita Kumar, Toby A Eyre et al.·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·Jun 1, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Alberto J Arribas, Eleonora Cannas, Giulio Sartori et al.·Blood·May 29, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.
Hyungwoo Cho, Koji Kato, Jason Yongsheng Chan et al.·Blood cancer journal·May 29, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.
Maria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi et al.·Cancers·May 28, 2026
Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.
Zoe Loh, Eliza Chung, Cameron Wellard et al.·Leukemia & lymphoma·May 26, 2026
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma.
Simone Ferrero, Riccardo Francia, Marco Ladetto et al.·Studies in health technology and informatics·May 21, 2026
First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.
·Cancer discovery·May 21, 2026
← PreviousPage 2 of 29Next →